LAVAL, Quebec--(BUSINESS WIRE)--Feb 23, 2021--

Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials. Vibegron is a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. The approval was announced by Urovant Sciences on December 23, 2020.

We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of patients,” said Amy Denvir, General Manager at Altasciences’ Kansas clinical pharmacology unit . “Working with Urovant Sciences on this program has been a pleasure, and we are delighted to see it come to fruition.

Altasciences’ expert clinical teams provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects. These trials were supported by Altasciences’ data services team, who performed the full data management and reporting for the associated clinical studies.

About Altasciences

Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210223005896/en/

CONTACT: Julie-Ann Cabana

Altasciences

+1 514 601-9763

jcabana@altasciences.com

KEYWORD: EUROPE UNITED STATES NORTH AMERICA CANADA

INDUSTRY KEYWORD: OTHER HEALTH RESEARCH PROFESSIONAL SERVICES PHARMACEUTICAL OTHER PROFESSIONAL SERVICES CLINICAL TRIALS SCIENCE BIOTECHNOLOGY FDA CONSULTING OTHER SCIENCE HEALTH

SOURCE: Altasciences

Copyright Business Wire 2021.

PUB: 02/23/2021 11:52 AM/DISC: 02/23/2021 11:52 AM

http://www.businesswire.com/news/home/20210223005896/en

Copyright Business Wire 2021.

Recommended for you

(0) comments

Welcome to the discussion.

Real Names required. No pseudonyms or partial names allowed. Stand behind what you post.
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.

Thank you for reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.